Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022Business Wire • 07/25/22
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in EuropeBusiness Wire • 07/22/22
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and PerformanceBusiness Wire • 07/14/22
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $250,000 to Contact the FirmNewsfile Corp • 06/14/22
AUPH ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in the Class Action Filed on Behalf of Aurinia Pharmaceuticals Inc. ShareholdersPRNewsWire • 06/14/22
Aurinia Pharmaceuticals Inc. Class Action: Levi & Korsinsky Reminds Aurinia Pharmaceuticals Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 14, 2022 - AUPHNewsfile Corp • 06/13/22
DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 06/13/22
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Aurinia Pharmaceuticals Inc. Investors of a Lead Plaintiff Deadline of June 14, 2022PRNewsWire • 06/13/22
AUPH FINAL DEADLINE JUNE 14: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - AUPHNewsfile Corp • 06/12/22
TUESDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 06/10/22
AUPH SHAREHOLDER ALERT: Jakubowitz Law Reminds Aurinia Pharmaceuticals Inc. Shareholders of a Lead Plaintiff Deadline of June 14, 2022PRNewsWire • 06/10/22
DEADLINE NEXT TUESDAY: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPHNewsfile Corp • 06/10/22
TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 06/09/22
AUPH LAWSUIT ALERT: Levi & Korsinsky Notifies Aurinia Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming DeadlinePRNewsWire • 06/09/22
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aurinia Pharmaceuticals Inc., of Class Action Lawsuit and Upcoming Deadline - AUPHPRNewsWire • 06/09/22
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aurinia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 14, 2022 - (NASDAQ: AUPH)PRNewsWire • 06/08/22
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA RecommendationsBusiness Wire • 06/03/22
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 06/01/22
ROSEN, A LEADING AND RANKED FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPHPRNewsWire • 05/31/22
Aurinia Pharmaceuticals Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 14, 2022 to Discuss Your Rights - AUPHNewsfile Corp • 05/30/22